IDL saw a comeback in TUBEX in Q3, and total sales came in SEK1m above our forecast, with OPEX relat...
Redeye provides an update following AcouSort’s Q4 2025 report, which showed higher-than-anticipated ...
Redeye comments on Sivers’ Q4 report, which showed solid FX-neutral growth and strong Photonics hard...
Redeye reviews BioInvent's Q4 report 2025. Following a string of positive readouts from BI-1206 and ...
Incap's Q4 net sales missed market consensus (LSEG Data & Analytics), but profitability was better t...
Ahead of Solwers' Q4 2025 report, we raise our EBIT estimates by 20-23% for 2026-27 on the back of t...
Fluoguide continued its track record of good cost control in Q4, and reported remaining cash and ST ...
Oriola’s Q4 was overall rather good, with double-digit growth exceeding expectations while profitabi...
Profitability (adj. EBIT margin) was better than market consensus (LSEG) expected in Q4.
Redeye states that the Q4 report landed in line with our expectations on net sales, with organic y/y...
Redeye comments on Better Collective’s Q4-results which were slightly ahead of expectations, support...
* Updates on Chematur, Konspec and the Candy producer * Lantmännen sparks hope for protein from feat...
Redeye returns with a full update following Medivir’s Q4 report.
Gofore’s Q4 provided the expected step-up in margins and leaves us thinking the worst could well be ...
As of today, Redeye will place its coverage of Serstech under review until further notice.
Redeye provides a research update following the recently published Q4 report from Lipum.
Redeye comments on AlzeCure Pharma receiving orphan drug designation (ODD) from the European Medicin...
Redeye comments on Sivers’ refinancing of its existing debt facilities into a new USD17m consolidate...
Nokian Panimo reports H2’25 figures on Friday. Despite the November profitability guidance cut, we e...
For 2026, the story remains the same: profitable sales growth for a company whose stock has dropped ...
